Description
CJC-1295 and ipamorelin are studied for complementary effects on growth-hormone signalling through GHRH and ghrelin-receptor pathways.
Potential Benefits — Research Is Ongoing
These are mechanistic possibilities from growth-hormone-releasing peptide research, not established human benefits of the CJC no-DAC/ipamorelin blend. Long-acting CJC-1295 DAC trial results do not validate the no-DAC form.
- Natural growth-hormone release: May stimulate the body’s own growth-hormone secretion.
- Growth-related tissue signalling: May influence downstream signals involved in tissue maintenance.
- Body-composition pathways: May influence growth-hormone-related fat and protein metabolism.
Research sources: Ipamorelin secretagogue study.
Research Overview
CJC-related GHRH analogues and ipamorelin are studied as growth-hormone secretagogues: compounds that stimulate hormone release rather than supply growth hormone directly. Published human experiments have measured hormone responses and pharmacokinetics of the individual compounds. They do not establish the benefits of this combined research presentation.
Mechanism / Pathway
GHRH analogues act through the growth-hormone-releasing hormone receptor, while ipamorelin acts through the ghrelin receptor pathway. These pathways influence pituitary GH secretion and downstream IGF-1 signalling. Changes in hormone levels are not themselves a measure of improved health or performance.
Important Research Information
The cited CJC-1295 trial studied a long-acting formulation. Its prolonged effects must not be attributed to no-DAC material or another analogue; exact chemical identity and formulation must be confirmed separately. The combination has not been validated by the cited trials for bodybuilding, sleep improvement or anti-ageing, and these studies do not establish human-use safety for this pen.
Published Research
- [1] Teichman et al. (2006): Long-acting CJC-1295 and GH/IGF-1 in healthy adults.
- [2] Gobburu et al. (1999): Ipamorelin pharmacokinetic/pharmacodynamic modelling in volunteers.
Scientific Profile
- Components: CJC-1295 5 mg + Ipamorelin 5 mg; 10 mg total
- Compound classes: GHRH-related analogue plus ghrelin-receptor agonist
- Identity limitation: Confirm the exact CJC variant from batch documentation; long-acting CJC-1295 findings cannot be assigned to no-DAC material
- Mixture identity: A blend has no single molecular formula or molecular weight
Research Areas
- GHRH and ghrelin-receptor signalling
- GH and downstream IGF-1 biomarker responses
- Variant-specific pharmacokinetics and limitations of combination research
Product Presentation
- Format: 3 mL prefilled disposable research pen
- Pen graduation: 300 clicks
- Research compound: CJC-1295 5 mg + Ipamorelin 5 mg (10 mg total)
- Storage: Keep refrigerated at 2–8°C and protect from light
Research-Use Notice
Compare CJC-1295 5 mg + Ipamorelin 5 mg with related listings
Check the complete ingredient names, individual amounts and presentation when comparing products. Total labelled contents do not specify the liquid volume or concentration.
View the separate CJC-1295 5 mg + Ipamorelin 5 mg vial listing or browse B&A Premium prefilled pens. These links help identify formats and ingredients; they do not establish that different products are interchangeable or that combining them is appropriate.
For a related listing, compare the CJC 5 mg + Ipamorelin 5 mg + Tesamorelin 2 mg pen. That listing includes Tesamorelin as a third labelled ingredient.
Warnings, Contraindications & Safety Information
Research use only. This is an evidence-limited safety summary, not a package insert, complete prescribing information or permission for self-administration. References to licensed medicines describe those specific products; they do not establish B&A product approval, equivalence or safety.
Contraindications & Who Should Avoid Exposure
A clinically validated contraindication list for this exact research presentation has not been established. That absence is not evidence of safety. Do not expose a person with a known allergy to a labelled ingredient or excipient.
Warnings & Precautions
This research presentation has not been established as safe for human administration. Do not use during pregnancy or breastfeeding, or in children. A serious medical condition, including cancer or significant liver or kidney disease, requires professional assessment; this page cannot establish suitability. CJC-1295 research documents GH/IGF-1 elevation. Clinical monitoring requirements and safety cannot be transferred between CJC variants or assumed for a CJC/ipamorelin blend.
Possible Adverse Reactions
Reliable frequencies and a complete human adverse-reaction profile for this exact product are unavailable. Allergy, local irritation and contamination-related harm remain possible; absence of reports does not establish absence of risk.
Drug & Supplement Interactions
Drug and supplement interactions have not been adequately characterised for this presentation. Do not assume that combining it with prescription medicines, hormones or other research compounds is safe. Give a clinician the full ingredient list if exposure has occurred.
When to Seek Urgent Help
Seek emergency care for difficulty breathing, swelling of the face or throat, collapse, severe persistent abdominal pain, or repeated vomiting with inability to keep fluids down. Stop further exposure and show the clinician the product label and ingredient list.
Handling & Storage Cautions
Follow the actual product label and batch-specific expiry information. Do not use damaged, contaminated or unexpectedly changed material. A clear appearance, refrigeration or addition of bacteriostatic water does not prove sterility, compatibility or a safe shelf life. Do not share needles, pens or opened material between people.
Safety references: Variant-specific CJC-1295 trial. Information reviewed 20 October 2026.
Reviews
There are no reviews yet.